Financial Data and Key Metrics Changes - Total revenue for 2025 reached $875.3 million, an 82% increase from $479.9 million in 2024 [5][22] - Net income increased to $70.8 million compared to $52.1 million in 2024 [5][28] - Adjusted EBITDA rose to $259.6 million, up 152.6% from $102.8 million in 2024 [6][29] - Cash on hand grew to $186 million as of December 31, 2025, up from $41 million a year earlier [8][42] Business Line Data and Key Metrics Changes - Hospital division revenue was $844.2 million in 2025, with mature hospitals increasing revenue by 73.4% [22][24] - Total patient visits increased to 188.3 thousand, an 11.8% rise from 168.4 thousand in 2024 [7][24] - Population health division revenue grew slightly by 0.7% to $31 million in 2025 [24] Market Data and Key Metrics Changes - The company reported a decrease in the current portion of long-term debt from $14.4 million to $13.3 million, while net long-term debt increased from $22.5 million to $29.2 million [8] - The ineligible claim submission rate for Nutex Health is approximately 8%, significantly better than the national average of 19% [10][38] Company Strategy and Development Direction - The company is focused on four priority areas: share repurchases, growth at existing hospitals, expansion of the Independent Physician Association (IPA), and real estate development strategy [15][18] - Nutex Health plans to open new hospitals in Jacksonville, West Little Rock, and San Antonio in 2026, with additional facilities planned for 2027 and 2028 [19][71] - The company aims to enhance its operational infrastructure to support higher throughput and a more diversified patient mix [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory challenges and optimize the Independent Dispute Resolution (IDR) process [20][63] - The company is optimistic about its growth trajectory entering 2026, supported by strong liquidity and operational improvements [20][42] Other Important Information - The company recognized a one-time $55 million revenue reduction related to arbitration claims deemed ineligible [9][30] - Total stock compensation expense for 2025 was $117 million, a significant increase from $16.6 million in 2024 [26] Q&A Session Summary Question: IDR-related submission rates and collection rates - The company noted a shift in IDR submission rates from 60%-70% to 50%-60%, with improved collection rates around 85% [56][60] - Management indicated that fewer submissions may reflect higher quality claims leading to better collections [62][65] Question: Reopening of a hospital in Texas - The decision to reopen was based on improved reimbursement through the IDR process and increased volume expectations [67][68] - Management confirmed they remain on track to open 5 to 6 facilities in 2026 and discussed a new real estate strategy to support this [71][72] Question: Timing of learning about the true-up adjustment - The company learned about the true-up adjustment in the middle of the fourth quarter, which was new information that required analysis before communication [77][79]

Financial Data and Key Metrics Changes - Total revenue for 2025 reached $875.3 million, an 82% increase from $479.9 million in 2024 [5][22] - Net income increased to $70.8 million compared to $52.1 million in 2024 [5][28] - Adjusted EBITDA rose to $259.6 million, up 152.6% from $102.8 million in 2024 [6][29] - Cash on hand grew to $186 million as of December 31, 2025, up from $41 million a year earlier [8][42] Business Line Data and Key Metrics Changes - Hospital division revenue was $844.2 million in 2025, with mature hospitals increasing revenue by 73.4% [22][24] - Total patient visits increased to 188.3 thousand, an 11.8% rise from 168.4 thousand in 2024 [7][24] - Population health division revenue grew slightly by 0.7% to $31 million in 2025 [24] Market Data and Key Metrics Changes - The company reported a one-time $55 million revenue reduction due to arbitration claims deemed ineligible [8][30] - The ineligible claim rate for Nutex Health is approximately 8%, significantly better than the national average of 19% [10][38] Company Strategy and Development Direction - The company focuses on four priority areas: share repurchases, growth at existing hospitals, expansion of the Independent Physician Association (IPA), and real estate development strategy [15][18] - Plans to open new hospitals in Jacksonville, West Little Rock, and San Antonio in 2026, with additional facilities planned for 2027 and 2028 [19][72] - The company aims to enhance its service offerings and operational efficiency to manage higher acuity patients effectively [50][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory challenges and maintain profitability [20] - The company is optimistic about the trajectory of growth as it enters 2026, carrying significant momentum from 2025 [20] - Management highlighted the importance of the Independent Dispute Resolution (IDR) process in improving reimbursement rates [12][66] Other Important Information - The company has remediated all previously disclosed material weaknesses in internal controls over financial reporting [22] - Total stock compensation expense for 2025 was $117 million, a significant increase from $16.6 million in 2024 [26] Q&A Session Summary Question: Can you explain the shift in IDR submission rates and collection rates? - Management noted that the submission rates decreased to 50%-60% with improved collection rates around 85%, indicating a trend towards resolving claims more efficiently [56][60][62] Question: What led to the reopening of the hospital in Texas? - The decision was based on improved reimbursement rates through the IDR process, making it a viable operation [66][68] Question: Are you on track to open the planned facilities in 2026? - Management confirmed that three locations are on track for 2026, with ongoing discussions about a new real estate strategy to support future openings [71][72]

Financial Data and Key Metrics Changes - Total revenue for 2025 reached $875.3 million, an 82% increase from $479.9 million in 2024 [5][22] - Net income increased to $70.8 million compared to $52.1 million in 2024 [5][28] - Adjusted EBITDA rose to $259.6 million, up 152.6% from $102.8 million in 2024 [6][29] - Cash on hand grew to $186 million as of December 31, 2025, up from $41 million a year earlier [7][41] Business Line Data and Key Metrics Changes - Hospital division revenue was $844.2 million in 2025, with mature hospitals increasing revenue by 73.4% [22][24] - Total patient visits increased by 11.8% to 188.3 thousand in 2025, with mature facilities growing by 1.3% [6][24] - Population health division revenue grew slightly by 0.7% to $31 million in 2025 [24] Market Data and Key Metrics Changes - The company reported a one-time $55 million revenue reduction in Q4 2025 due to arbitration claims deemed ineligible [8][30] - The ineligible claim rate for Nutex Health is approximately 8%, significantly better than the national average of 19% [10][37] Company Strategy and Development Direction - The company focuses on four priority areas for capital allocation: share repurchases, growth at existing hospitals, expansion of the Independent Physician Association (IPA), and real estate development [15][18] - Nutex Health operates 27 hospital facilities across 12 states and plans to open new hospitals in 2026 and beyond [19][70] - The company aims to enhance its service offerings and improve patient access through targeted investments in various healthcare services [16][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory challenges and optimize the Independent Dispute Resolution (IDR) process [20][60] - The company is optimistic about its growth trajectory entering 2026, carrying significant momentum from 2025 [20][70] Other Important Information - The company successfully remediated previously disclosed material weaknesses in internal controls over financial reporting in 2025 [22] - Total stock compensation expense for 2025 was $117 million, a significant increase from $16.6 million in 2024 [26] Q&A Session Summary Question: Clarification on IDR submission rates and collection rates - Management noted that submission rates decreased to 50%-60% with improved collection rates around 85%, indicating a shift towards higher quality claims [55][60] Question: Insights on the reopening of a hospital in Texas - The decision to reopen was based on improved reimbursement through the IDR process and better operational capabilities [66][67] Question: Confirmation on the timeline for new hospital openings - Management confirmed plans to open three hospitals in 2026 and additional facilities in 2027 and 2028, supported by a new real estate strategy [69][70]

Core Viewpoint - Nutex Health Inc. has faced significant share price decline following a critical report by Blue Orca Capital, which raised concerns about the company's practices related to independent dispute resolution vendor HaloMD and its financial health [1][5]. Group 1: Financial Impact and Investigations - Following the implementation of the No Surprises Act (NSA) on January 1, 2022, Nutex experienced a decline in average payments by insurers for emergency services, with a decrease of approximately 26% by the end of 2022 and about 19% by the end of 2023 [3][4]. - Nutex's annual report for March 31, 2025, indicated a refined estimate of revenue recognition, which increased revenue and net income before tax for the year ended December 31, 2024, by approximately $169.7 million and $112.0 million, respectively [5]. - Blue Orca's report suggested that Nutex's revenue may be largely uncollectible, highlighting a massive receivables balance of uncollected awards, which poses significant risk to the company [5]. Group 2: Legal and Regulatory Concerns - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Nutex misled investors regarding its compliance with the NSA and the propriety of its actions [2][6]. - Blue Orca identified HaloMD, Nutex's IDR vendor, as being involved in serious legal issues, including accusations of theft, fraud, and racketeering, which could potentially implicate Nutex in future litigation [5].